Kanawha Capital Management LLC Has $24.87 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Kanawha Capital Management LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 149,938 shares of the company's stock after purchasing an additional 4,079 shares during the quarter. Johnson & Johnson accounts for 1.9% of Kanawha Capital Management LLC's investment portfolio, making the stock its 12th biggest position. Kanawha Capital Management LLC's holdings in Johnson & Johnson were worth $24,866,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Brighton Jones LLC lifted its position in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares during the period. Hudson Value Partners LLC boosted its holdings in Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after acquiring an additional 1,022 shares during the period. Bedel Financial Consulting Inc. raised its holdings in Johnson & Johnson by 7.0% in the 4th quarter. Bedel Financial Consulting Inc. now owns 14,878 shares of the company's stock valued at $2,301,000 after acquiring an additional 973 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Johnson & Johnson by 3.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 18,187,082 shares of the company's stock worth $2,630,216,000 after acquiring an additional 547,714 shares during the period. Finally, Bahl & Gaynor Inc. raised its position in Johnson & Johnson by 303.0% in the fourth quarter. Bahl & Gaynor Inc. now owns 1,328,414 shares of the company's stock worth $192,115,000 after purchasing an additional 998,761 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded down $0.78 during trading on Monday, reaching $155.23. 6,263,851 shares of the stock were exchanged, compared to its average volume of 8,052,601. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The firm has a market cap of $373.49 billion, a PE ratio of 17.27, a PEG ratio of 2.36 and a beta of 0.41. The stock has a 50-day moving average price of $153.67 and a 200-day moving average price of $154.24. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. Research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.35%. Johnson & Johnson's dividend payout ratio is 57.84%.

Analyst Ratings Changes

Several analysts have recently commented on JNJ shares. Morgan Stanley increased their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 16th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price target for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Raymond James Financial lowered their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Barclays lowered their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 17th. Finally, Wall Street Zen upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st. Eleven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.